These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 26791869)

  • 21. Functional bioassays for immune monitoring of high-risk neuroblastoma patients treated with ch14.18/CHO anti-GD2 antibody.
    Siebert N; Seidel D; Eger C; Jüttner M; Lode HN
    PLoS One; 2014; 9(9):e107692. PubMed ID: 25226154
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice.
    Zeng Y; Fest S; Kunert R; Katinger H; Pistoia V; Michon J; Lewis G; Ladenstein R; Lode HN
    Mol Immunol; 2005 Jul; 42(11):1311-9. PubMed ID: 15950727
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma.
    Navid F; Sondel PM; Barfield R; Shulkin BL; Kaufman RA; Allay JA; Gan J; Hutson P; Seo S; Kim K; Goldberg J; Hank JA; Billups CA; Wu J; Furman WL; McGregor LM; Otto M; Gillies SD; Handgretinger R; Santana VM
    J Clin Oncol; 2014 May; 32(14):1445-52. PubMed ID: 24711551
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Validated detection of human anti-chimeric immune responses in serum of neuroblastoma patients treated with ch14.18/CHO.
    Siebert N; Eger C; Seidel D; Jüttner M; Lode HN
    J Immunol Methods; 2014 May; 407():108-15. PubMed ID: 24727144
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dexmedetomidine and hydromorphone: a novel pain management strategy for the oncology ward setting during anti-GD2 immunotherapy for high-risk neuroblastoma in children.
    Görges M; West N; Deyell R; Winton P; Cheung W; Lauder G
    Pediatr Blood Cancer; 2015 Jan; 62(1):29-34. PubMed ID: 25263424
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dinutuximab: A Review in High-Risk Neuroblastoma.
    Hoy SM
    Target Oncol; 2016 Apr; 11(2):247-53. PubMed ID: 26891967
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of human-mouse chimeric anti-GD2 mAb ch14.18 in a phase I trial in neuroblastoma patients.
    Uttenreuther-Fischer MM; Huang CS; Yu AL
    Cancer Immunol Immunother; 1995 Dec; 41(6):331-8. PubMed ID: 8635190
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032.
    Yu AL; Gilman AL; Ozkaynak MF; Naranjo A; Diccianni MB; Gan J; Hank JA; Batova A; London WB; Tenney SC; Smith M; Shulkin BL; Parisi M; Matthay KK; Cohn SL; Maris JM; Bagatell R; Park JR; Sondel PM
    Clin Cancer Res; 2021 Apr; 27(8):2179-2189. PubMed ID: 33504555
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics and pharmacogenetics of 13-cis retinoic acid in Indian high-risk neuroblastoma patients.
    Gota V; Chinnaswamy G; Vora T; Rath S; Yadav A; Gurjar M; Veal G; Kurkure P
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):763-8. PubMed ID: 27541143
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma.
    Yu AL; Uttenreuther-Fischer MM; Huang CS; Tsui CC; Gillies SD; Reisfeld RA; Kung FH
    J Clin Oncol; 1998 Jun; 16(6):2169-80. PubMed ID: 9626218
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma.
    Simon T; Hero B; Faldum A; Handgretinger R; Schrappe M; Niethammer D; Berthold F
    J Clin Oncol; 2004 Sep; 22(17):3549-57. PubMed ID: 15337804
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Role of Nursing Professionals in the Management of Patients With High-Risk Neuroblastoma Receiving Dinutuximab Therapy.
    Secola R; Marachelian A; Cohn SL; Toy B; Neville K; Granger M; Brentlinger A; Martin G
    J Pediatr Oncol Nurs; 2017; 34(3):160-172. PubMed ID: 28061552
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanisms, Characteristics, and Treatment of Neuropathic Pain and Peripheral Neuropathy Associated with Dinutuximab in Neuroblastoma Patients.
    Mastrangelo S; Rivetti S; Triarico S; Romano A; Attinà G; Maurizi P; Ruggiero A
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884452
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Local delivery of dinutuximab from lyophilized silk fibroin foams for treatment of an orthotopic neuroblastoma model.
    Ornell KJ; Taylor JS; Zeki J; Ikegaki N; Shimada H; Coburn JM; Chiu B
    Cancer Med; 2020 Apr; 9(8):2891-2903. PubMed ID: 32096344
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination therapy with interleukin-2 and antitumor monoclonal antibodies.
    Sondel PM; Hank JA
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S121-7. PubMed ID: 9457407
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma.
    Saleh MN; Khazaeli MB; Wheeler RH; Allen L; Tilden AB; Grizzle W; Reisfeld RA; Yu AL; Gillies SD; LoBuglio AF
    Hum Antibodies Hybridomas; 1992 Jan; 3(1):19-24. PubMed ID: 1576319
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In brief: Dinutuximab (Unituxin) for high-risk neuroblastoma.
    Med Lett Drugs Ther; 2016 Mar; 58(1491):e48. PubMed ID: 27027692
    [No Abstract]   [Full Text] [Related]  

  • 38. Infants with stage 4 neuroblastoma: the impact of the chimeric anti-GD2-antibody ch14.18 consolidation therapy.
    Simon T; Hero B; Faldum A; Handgretinger R; Schrappe M; Niethammer D; Berthold F
    Klin Padiatr; 2005; 217(3):147-52. PubMed ID: 15858706
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analytical characterization of ch14.18: a mouse-human chimeric disialoganglioside-specific therapeutic antibody.
    Soman G; Kallarakal AT; Michiel D; Yang X; Saptharish N; Jiang H; Giardina S; Gilly J; Mitra G
    MAbs; 2012; 4(1):84-100. PubMed ID: 22327432
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
    Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
    Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.